A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer

Phase Ii ◽

Phase Ii Trial ◽

Open Label ◽

Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-014-2391-2 ◽

2014 ◽

Vol 73 (4) ◽

pp. 695-702 ◽

Cited By ~ 16

Author(s):

Carlos R. Becerra ◽

Ramon Salazar ◽

Rocio Garcia-Carbonero ◽

Anne L. Thomas ◽

Federico J. Vázquez-Mazón ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Open Label ◽

Open Label Phase ◽

Previously Treated

An Open‐Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX‐6 as First‐Line Therapy for Metastatic Colorectal Cancer

The Oncologist ◽

10.1634/theoncologist.2014-0028 ◽

2014 ◽

Vol 19 (4) ◽

pp. 350-351 ◽

Cited By ~ 37

Author(s):

Rocio Garcia‐Carbonero ◽

Fernando Rivera ◽

Joan Maurel ◽

Jean‐Pierre M. Ayoub ◽

Malcolm J. Moore ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

Open Label ◽

Safety And Efficacy ◽

First Line Therapy ◽

Line Therapy ◽

Efficacy and saftey of capecitabine, oxaliplatin, and irinotecan (xeloxiri) as salvage therapy for patients with treatment-refractory metastatic colorectal cancer: A prospective, open-label, phase II study.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e14511 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e14511-e14511

Author(s):

Thomas Cheung Yau ◽

Vikki YF Tang ◽

Joanne Chiu ◽

Hilda Wong ◽

Roland Ching-Yu Leung

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Salvage Therapy ◽

Phase Ii Study ◽

Open Label ◽

Open Label Phase ◽

Treatment Refractory

3046 POSTER A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX6 + Cetuximab versus FOLFIRI + Cetuximab as first-line therapy in patients with metastatic colorectal cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)70974-6 ◽

2007 ◽

Vol 5 (4) ◽

pp. 249 ◽

Cited By ~ 1

Author(s):

T.E. Ciuleanu ◽

W. Scheithauer ◽

G. Kurteva ◽

J. Ocvirk ◽

I. Koza ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽

An open-label phase II study of intermittent oral capecitabine (X) as first-line treatment for patients (pts) with metastatic colorectal cancer (MCRC)

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3730 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3730-3730

Author(s):

G. Zhongzhen ◽

F. Fengyi ◽

L. Xiaoqing ◽

W. Yajie ◽

Y. Baoming ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Oral Capecitabine ◽

Open Label Phase ◽

First Line Treatment

Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial

Oncology ◽

10.1159/000507293 ◽

2020 ◽

Vol 98 (9) ◽

pp. 637-642

Author(s):

Sotaro Sadahiro ◽

Toshiyuki Suzuki ◽

Kazutake Okada ◽

Gota Saito ◽

Hiroshi Miyakita ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

First Line ◽

Open Label ◽

Randomized Phase Ii ◽

Line Chemotherapy

523TiP MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2066 ◽

2020 ◽

Vol 31 ◽

pp. S460-S461

Author(s):

J. Strickler ◽

K. Ng ◽

A. Cercek ◽

C. Fountzilas ◽

F. Sanchez ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Her2 Positive ◽

Open Label ◽

Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-3416 ◽

2021 ◽

Author(s):

Sophie Cousin ◽

Coralie Cantarel ◽

Jean-Philippe Guegan ◽

Carlos Gomez-Roca ◽

Jean-Philippe Metges ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Open Label ◽

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697918.793457734 ◽

2012 ◽

Author(s):

Hans-Joachim Schmoll

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Dose Dense ◽

First Line Treatment

Bendamustine, Followed by Ofatumumab and Ibrutinib in Chronic Lymphocytic Leukaemia (CLL2-BIO): Primary Endpoint Analysis of a Multicentre, Open-Label Phase-II Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3335059 ◽

2019 ◽

Author(s):

Paula Cramer ◽

Julia V. Tresckow ◽

Sandra Robrecht ◽

Jasmin Bahlo ◽

Moritz Fürstenau ◽

...

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

Phase Ii ◽

Primary Endpoint ◽

Lymphocytic Leukaemia ◽

Phase Ii Trial ◽

Open Label ◽